"10.1371_journal.pone.0050970","plos one","2012-12-04T00:00:00Z","P Roberto Bakker; Asmar F Y Al Hadithy; Najaf Amin; Cornelia M van Duijn; Jim van Os; Peter N van Harten","Psychiatric Centre GGZ Centraal, Amersfoort, The Netherlands; Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands; Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands; Department of Psychiatry and Psychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Psychosis Studies, Institute of Psychiatry, Kings Health Partners, Kings College London, London, United Kingdom","Conceived and designed the experiments: PRB AAH NA CMvD JvO PNvH. Performed the experiments: PRB. Analyzed the data: PRB NA CMvD JvO PNvH. Contributed reagents/materials/analysis tools: PRB AAH. Wrote the paper: PRB AAH NA CMvD JvO PNvH.","P. Roberto Bakker, Asmar F.Y. Al Hadithy, Najaf Amin and Cornelia M. van Duijn have declared that no competing interests exist. The authors have read the journals policy and have the following conflicts: Jim van Os is/has been an unrestricted research grant holder with, or has received financial compensation as an independent symposium speaker from Eli Lilly, BMS, Lundbeck, Organon, Janssen-Cilag, GSK, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. Peter N. van Harten has received financial compensation as an independent symposium speaker from Eli Lilly, BMS, Janssen-Cilag, GSK, and AstraZeneca, companies that have an interest in the treatment of psychosis. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","P Roberto Bakker","PRB",6,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
